ClinicalTrials.gg
Status unknownNCT02199925Updated Apr 16, 2015

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

A Phase 4 interventional study of Gammaplex 5% in Autism, Autistic Disorder and Asperger's Disorder, sponsored by Isaac Melamed. Status unknown at 1 site in United States. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2015-04-16.

Sponsored by Isaac Melamed · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2015), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
4 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Planned enrollment
316th of 504
30 · median 44
Started
2013
with 29 others
Phase 4
18 of 603
3 open now
Registered
262nd of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 316th largest by planned enrollment of the 504 interventional ones that give a count, is one of 30 that started in 2013, is one of 18 in phase 4, and was the 262nd registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 4 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

If autism is the consequence of a chronic inflammatory process preventing the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. IGIV treatment has been known to suppress inflammation and has been used in the treatment of inflammatory conditions and autoimmune diseases.

Read the detailed description

We have come to believe that an immature immune system with abnormal signaling and altered apoptotic pathways may result in a process of neuroinflammation with a clinical presentation of Autism Spectrum Disorder. If Autism Spectrum Disorders are the consequence of a chronic inflammatory process that prevents the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. We believe that there is a correlation between immunological abnormalities and the development of the autism.

03

Conditions studied

  • Autism
  • Autistic Disorder
  • Asperger's Disorder
  • PDD
  • Pervasive Developmental Disorder

Keywords

  • Autism
  • Autism spectrum
  • Autism children
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is between the ages of or equal to 4 and 12 years of age, of either gender, and belonging to any ethnic group.
  • The subject has a diagnosis, for a minimum of 6 months prior to screening, of either autistic disorder, Asperger disorder, or pervasive developmental disorder (PDD).
  • Normal physical test results.
  • Immunological lab results showing reduced levels of activated 0L or abnormal lymphocyte stimulation, or T or B cell dysfunction (hypgammaglobulinemia, primary immunodeficiency (PIDD), or common variable immune deficiency (CVID).

Exclusion criteria

Exclusion Criteria:

  • A diagnosis of isolated IGA deficiency
  • Allergic reactions to blood products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Gammaplex 5% IGIV

    Gammaplex 5% IGIV administered intravenously

    Drug: Gammaplex 5%

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction.

    The primary endpoint is disease improvement, as evidenced by standardized test measures across 3 intervals: screening for baseline measurements, visit 5, and end of study visit measurements. Primary efficacy variables will be measured using the following standardized tests 1. Caregiver Scales (SRS, CCC-2, ABC) 2. CGI-S and CGI - I 3. PPVT 4. ADOS

    Time frame: 1 year

Secondary outcomes

  1. The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation.

    Time frame: 1 year

Other outcomes

  1. To improve development in autistic spectrum

    Time frame: 1 year

07

Study locations

1 site
  • IMMUNOe International Research Centers
    Centennial, Colorado 80112, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Apr 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 25, 2014
Start
Jun 2013
Primary completionEst.
Apr 2015
CompletionEst.
Jul 2015
Last update
Apr 16, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02199925
Lead sponsor
Isaac Melamed
Collaborators
Bio Products Laboratory
Responsible party
Isaac Melamed (Principal Investigator, IMMUNOe Research Centers) — Sponsor-investigator
First posted
Jul 25, 2014
Start date
Jun 2013
Primary completion
Apr 2015 (estimated)
Completion
Jul 2015 (estimated)
Last update
Apr 16, 2015

Study contacts

Isaac Melamed, MD
principal investigator · IMMUNOe International Clinical Research Centers

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion